Bausch + Lomb

362 articles about Bausch + Lomb

• 

  FDA Approves Bausch + Lomb, Novaliq Dry Eye Disease Drug

  5/19/2023

  The regulator’s approval makes Miebo the first DED treatment that directly addresses tear evaporation. The drug is expected to hit U.S. markets in the second half of 2023.

• Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

  5/3/2023

  Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2023 financial results.

• Bausch + Lomb Releases Annual Environmental, Social and Governance Report

  5/1/2023

  Bausch + Lomb Corporation, today released its annual Environmental, Social and Governance (ESG) Report, highlighting the Company’s ongoing commitment to implement sustainable business practices and initiatives that support its stakeholders’ well-being.

• Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

  4/26/2023

  Bausch + Lomb Corporation today announced the presentation of 21 podium presentations and four poster presentations related to the company’s products and pipeline programs during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in San Diego from May 5-8, 2023.

• Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

  4/25/2023

  Bausch + Lomb Corporation today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023.

• Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

  4/24/2023

  Bausch + Lomb Corporation today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

• Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

  4/20/2023

  Bausch + Lomb Corporation today announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.

• Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

  4/17/2023

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023.

• Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma™ Fully Digital Surgical Visualization Platform

  4/13/2023

  Bausch + Lomb and Heidelberg Engineering Announce the Introduction of SeeLuma ™ Fully Digital Surgical Visualization Platform.

• Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

  4/12/2023

  Bausch + Lomb Corporation announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023.

• Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

  3/22/2023

  Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology.

• Bausch + Lomb Announces Fourth-Quarter and Full-Year 2022 Results

  2/22/2023

  Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”, “we” or “our”), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2022 financial results.

• New Bausch + Lomb Social Media Campaign Highlights What ‘Sights’ Inspire AMD Patients

  2/7/2023

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced a new social media campaign designed to raise awareness of Age-related Macular Degeneration, a leading cause of vision loss for those over age 50 and the leading cause of blindness for the 65+ population.

• Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection)

  2/1/2023

  Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE ® (Verteporfin for Injection).

• Bausch + Lomb Acquires AcuFocus, Inc.

  1/17/2023

  Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

• Bausch + Lomb Introduces Enhanced PreserVision® AREDS 2 Formula Mini Soft Gels with OCUSorb™

  1/9/2023

  Bausch + Lomb Introduces Enhanced PreserVision ® AREDS 2 Formula Mini Soft Gels with OCUSorb ™.

• Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference

  1/9/2023

  Bausch + Lomb Publishes Update Presentation for the 41st Annual J.P. Morgan Healthcare Conference.

• Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference

  1/5/2023

  Bausch + Lomb Announces Participation at the 41st Annual J.P. Morgan Healthcare Conference.

• Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology

  1/4/2023

  Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmology.

• Bausch + Lomb Amends CEO Separation Agreement

  12/22/2022

  Bausch + Lomb Corporation announced that the Company and its CEO, Joseph C. Papa, have entered into an Amended and Restated Separation Agreement, pursuant to which Mr. Papa has agreed to continue serving as CEO until at least March 4, 2023 and lasting until such date as the Board of Directors of the Company determines in its discretion or his successor is appointed, but no later than June 30, 2023.